InvestorsHub Logo
icon url

dndodd

07/08/20 7:51 AM

#443 RE: Sluicebox #442

As much as I follow Endra I am not qualified to properly interpret the results of a clinical trial I rely on the investor presentation; https://s3.amazonaws.com/cdn.irdirect.net/PIR/957/4471/ENDRA%20Life%20Sciences%20Investor%20Presentation%20June%202020.pdf

It is my understanding TAEUS is very close to being as good as an MRI in quantifying liver fat which depending on who you talk to is considered the gold standard for liver fat. Other clinicians have said the liver biopsy is considered the gold standard but they may also be trying to check for fibrosis at the same time.

I found a you tube presentation on Liver Disease -The Silent epidemic By a Dr from UCSF to be very educational I believe her name is Danielle Brandman.
Beyond that reach out to Endra for answers they are generally very responsive.
icon url

dndodd

07/08/20 8:06 AM

#444 RE: Sluicebox #442

The only persons I have come across that is qualified to answer your questions is someone from Endra or there is a poster on Stocktwits - GenomeGuru who I believe is qualified to give you a good answer.
icon url

biotech_researcher

07/11/20 7:12 AM

#448 RE: Sluicebox #442

"Is it just me or anyone else questioning the TAEUS' ability to accurately quantify liver fat. Read the clinical trial posted on their website. Seems to me that they are missing about 20% of patients with liver fat >6%. This explains a lot.....